The liver fulfills many vital processes in mammals. It is the central organ of energy metabolism, responsible for the maintenance of the blood sugar level and the synthesis of plasma proteins under physiological and pathophysiological conditions.
Hepatocytes are the most prominent cells within the liver. Hepatocytes eliminate toxic substances from the blood. In this biotransformation process transporter proteins (influx and efflux transporter), phase I reactions (cytochrome P450 proteins), phase II reactions (mainly glucuronidation and sulfatation) play a central role.
Cryopreserved primary hepatocytes are ideally suited for in vitro metabolism and toxicity/detoxification studies before preclinical or clinical tests.
PRIMACYT is one of the pioneers in the development of advanced in vitro model systems. We are a leading company in the field of research of human and animal hepatocytes. We offer fresh and cryopreserved animal hepatocytes in suspension and plated.
PRIMACYT is approved by the European Commission as an EU Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) since 2013 and serves as a member of the laboratory network responsible for the method validation.
Our colleagues are professionals and undergo continuous training in the preparation, isolation, and cryopreservation of hepatocytes in general, including related co-products, methods, and tools. We are a GLP certified laboratory since 2006.
In drug development, at least two in vivo repeated-dose toxicity studies of a drug candidate have to be performed in two different animal species before human studies can be initiated (https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292340.pdf). In most cases these species are mouse or rat and dog or monkey.
Hepatotoxicity is a major cause for failure in drug development. For interpretation of hepatotoxicity data, it is important to understand potential interspecies differences in mechanisms that lead to drug toxicity. This includes
– drug uptake into the liver,
– biotransformation of the drug (Phase I and Phase II), and
– drug efflux from the liver
Interspecies differences in expression and activities in transport proteins and biotransformation enzymes may result in different intra- and extrahepatic concentrations of the drug.
Quantification of drug transporter protein by LC/MS has revealed significant interspecies differences in the expression of uptake and efflux transporters. On the other hand, in beagle hepatocytes expression of the two most important Organic Anion Transporters Oatp1a2 and Oatp1b4 (equivalent to human OATP1B1 and OATP1B3) was maintained at the same level as in dog liver tissue (Wang et al. 2014).
Wang L, Prasad B, Salphati L, Chu X, Gupta A, Hop C E.C.A., Evers R, and Unadkat J. D.: Interspecies Variability in Expression of Hepatobiliary Transporters across Human, Dog, Monkey, and Rat as Determined by Quantitative Proteomics, Drug Metab. Dispos., 2015, 43:367–374
PRIMACYT offers cryopreserved Cynomolgus hepatocytes from single donors. Hepatocytes from individual donors are comprehensively tested for viability, plateability, use in suspension cultures, drug transporter and biotransformation (Cytochrome P450 Phase I activities) and suitability for 3D spheroid cultures.
Monkey hepatocytes are isolated from livers obtained from male or female Cynomolgus and are cryopreserved directly after isolation. Donor demographics stating vaccination status and health status of the animals are available for each animal. Cryopreserved Cynomolgus hepatocytes are used in suspension assays and plated in 2D and 3D cell cultures.
This info refers to the product data below:
- Inventory: Number of vials available as of date of last update. Availability of vials may have changed since that date by interim orders.
- Viability: Denotes post thaw results using the thawing protocol for hepatocytes.
- To print lot information, please select the print icon at the end of the lists below. For research use only.
- Not intended for human or animal diagnostic or therapeutic use.
Follow this link to contact us for direct Questions or inquire about your Project information. Thank you.
This info refers to the product data below:
Showing 1 - 18 out of 18
Page 1 out of 1
Product Code | Lot | Sex | Inventory (vials) | Viability (%) | Recovery (Viable cells/vial) | plateable 24well | plateable 96well | 3D culture | CYP1A1/1A2 induction Xfold | Price (€) | Quantity | Action |
---|---|---|---|---|---|---|---|---|---|---|---|---|
CHCS
|
male
|
7 in stock |
96.5
|
> 6 Mio.
|
no
|
no
|
no
|
-
|
678,00 €
|
|
||
CHCS
|
female
|
3 in stock |
91.9
|
> 4 Mio.
|
no
|
no
|
no
|
-
|
452,00 €
|
|
||
CHCP-I-3D
|
male
|
27 in stock |
97.9
|
> 4 Mio.
|
yes
|
yes
|
yes
|
5.3
|
664,00 €
|
|
||
CHCS
|
female
|
4 in stock |
92.2
|
> 6 Mio.
|
no
|
no
|
no
|
-
|
678,00 €
|
|
||
CHCP-I-3D
|
female
|
119 in stock |
93.3 +/- 0.8
|
> 4 Mio.
|
yes
|
yes
|
yes
|
2.8
|
664,00 €
|
|
||
CHCP-I-T
|
female
|
2 in stock |
90.3
|
> 4 Mio.
|
yes
|
yes
|
not tested
|
19.7
|
604,00 €
|
|
||
CHCP-I
|
female
|
48 in stock |
97.3 +/- 0.3
|
> 4 Mio.
|
yes
|
yes
|
no
|
2.3
|
632,50 €
|
|
||
CHCP-I
|
female
|
2 in stock |
95.4
|
> 6 Mio.
|
yes
|
yes
|
not tested
|
18.7
|
950,00 €
|
|
||
CHCP-I
|
female
|
3 in stock |
96.5
|
> 4 Mio.
|
yes
|
yes
|
not tested
|
16.3
|
632,50 €
|
|
||
CHCP-I-T
|
male
|
18 in stock |
84.1 +/- 5.1
|
> 6 Mio.
|
yes
|
no
|
no
|
6.0
|
980,00 €
|
|
||
CHCS
|
male
|
17 in stock |
91.9 +/- 2.2
|
> 6 Mio.
|
no
|
no
|
not tested
|
-
|
678,00 €
|
|
||
CHCS
|
female
|
13 in stock |
85.7 +/- 1.9
|
> 4 Mio.
|
no
|
no
|
not tested
|
-
|
452,00 €
|
|
||
CHCP-I
|
male
|
9 in stock |
97
|
> 6 Mio.
|
yes
|
no
|
not tested
|
3.2
|
950,00 €
|
|
||
CHCP-I-3D
|
male
|
42 in stock |
93.3
|
> 2 Mio.
|
yes
|
yes
|
yes
|
16.4
|
348,00 €
|
|
||
CHCP-I
|
male
|
22 in stock |
85.4
|
> 6 Mio.
|
yes
|
yes
|
no
|
8.0
|
996,00 €
|
|
||
CHCP-I
|
female
|
6 in stock |
88.2
|
> 4 Mio.
|
yes
|
no
|
not tested
|
10.5
|
632,50 €
|
|
||
CHCP-I
|
female
|
3 in stock |
92.1
|
> 4 Mio.
|
yes
|
no
|
not tested
|
3.0
|
632,50 €
|
|
||
CHCP-I
|
female
|
3 in stock |
88.2
|
> 6 Mio.
|
yes
|
yes
|
not tested
|
22.5
|
950,00 €
|
|
CHCP-I-T – Cynomolgus hepatocytes cryopreserved plateable Cytochrome P45o inducible and Transporter qualified
CHCP-I-3D – Cynomolgus hepatocytes cryopreserved plateable Cytochrome P45o inducible and 3D (Spheroid culture) qualified
CHCP-I – Cynomolgus hepatocytes cryopreserved plateable Cytochrome P45o inducible
CHCS – Cynomolgus hepatocytes cryopreserved for use in suspension assays